FindTrial
Sign In

Study on therapeutic drug monitoring and adverse drug reactions of linezolid in adult patient

Study on therapeutic drug monitoring and hematological toxicity of linezolid in adult patient

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100052326
Enrollment
Unknown
Registered
2021-10-24
Start date
2019-04-01
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Therapeutic drug monitoring and adverse drug reactions of linezolid

Interventions

Case series:No

Sponsors

Yan Qin
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 92 Years

Inclusion criteria

Inclusion criteria: Patients aged >=18 years old, receiving linezolid therapy >=3 days orally or intravenous infusion.

Exclusion criteria

Exclusion criteria: Patients aged < 18 years old, pregnant, diagnosed with hematological diseases (haemato-oncologic disease, myelosuppression, and disseminated intravascular coagulation) or chemo/radiotherapy within two weeks prior to the initiation of linezolid therapy were excluded from the study.

Design outcomes

Primary

MeasureTime frame
Thrombocytopenia;Anemia;—

Countries

China

Contacts

Public ContactQin Yan

Zhongshan Hospital, Fudan University

celeryan@163.com+86 13817148763

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026